Annales De Dermatologie Et De Venereologie最新文献

{"title":"Pseudolymphoma following laser removal of red tattoo ink","authors":"S. Berros , M. Schollhammer , C. Bocciarelli , G. Le Flahec , N. Kluger , L. Misery , E. Brenaut","doi":"10.1016/j.annder.2025.103461","DOIUrl":"10.1016/j.annder.2025.103461","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103461"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145972943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pseudoxanthoma elasticum — The skin as a sentinel of systemic disease","authors":"C. Bodemer","doi":"10.1016/j.annder.2026.103475","DOIUrl":"10.1016/j.annder.2026.103475","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103475"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant ipilimumab and nivolumab for resectable stage II mucosal melanoma","authors":"M. Amiot , C. Halimi , A. Chaud , A. Guyard , K. Ben-Ali , C. Faucon , F. Brunet-Possenti","doi":"10.1016/j.annder.2025.103444","DOIUrl":"10.1016/j.annder.2025.103444","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103444"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145622341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic patient education through digital technology: Recommendations for paediatrics and dermatology","authors":"H. Dufresne ,&nbsp;C. Godot ,&nbsp;J. Mashiah ,&nbsp;S. Dimarcq ,&nbsp;C. Bodemer ,&nbsp;S. Hadj-Rabia","doi":"10.1016/j.annder.2025.103419","DOIUrl":"10.1016/j.annder.2025.103419","url":null,"abstract":"<div><h3>Background</h3><div>Therapeutic patient education (TPE) in pediatrics is part of the healthcare pathway, from diagnosis in childhood to adulthood. The COVID-19 pandemic accelerated the development of digital TPE. The framework for digital TPE (e-TPE) remains to be defined.</div></div><div><h3>Objectives</h3><div>Suggest key points for organizing and running e-TPE programs.</div></div><div><h3>Patients and methods</h3><div>A monocentric prospective study was conducted in adolescents with a chronic skin disease, as well as their parents and healthcare professionals participating in an e-TPE program. Participants answered open questions either during a one-on-one session (patients and parents) or via a questionnaire (healthcare professionals).</div></div><div><h3>Results</h3><div>Twenty-three parents were included: eleven adolescents and sixteen healthcare professionals. Parents, patients, and healthcare professionals showed a preference for remote TPE sessions. The familiar home environment facilitates the learning process. However, professional access to privacy can be a source of discomfort. The technical aspect presents a major obstacle for both healthcare professionals and parents.</div></div><div><h3>Discussion and conclusion</h3><div>Access to TPE is enhanced by e-tools, which facilitate the participation of parents, expert patient partners, associations, and other professionals. Travel costs and possible scheduling conflicts are easily overcome, further harmonizing care. In this way, remote TPE sessions should enhance the development of the city-hospital network. Importantly, participant age is a key point in terms of screen time (age &lt; 6 years), concentration/remobilization in front of a computer screen (age &lt; 10 years), technical difficulties, and digital illiteracy (across the entire population). Confidentiality, parental information, and invasion of privacy must be considered.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103419"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145920958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk for attention deficit hyperactivity disorder in alopecia areata patients: A nationwide case-control study","authors":"Y. Wohl ,&nbsp;J. Mashiah ,&nbsp;R. Wohl ,&nbsp;A. Maruani ,&nbsp;A. Bentov","doi":"10.1016/j.annder.2025.103439","DOIUrl":"10.1016/j.annder.2025.103439","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103439"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147282054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of sleep disorders in patients with bullous pemphigoid","authors":"M. Alqahtani ,&nbsp;M. Viguier ,&nbsp;G. Chaby ,&nbsp;G. Jeudy ,&nbsp;C. Bedane ,&nbsp;M. Alexandre ,&nbsp;C. Picard-Dahan ,&nbsp;S. Duvert Lehembre ,&nbsp;C. Abasq ,&nbsp;G. Quéreux ,&nbsp;H. Maillard ,&nbsp;J.L. Perrot ,&nbsp;C. Couzan ,&nbsp;A. Pham-Ledard ,&nbsp;V. Hebert ,&nbsp;P. Joly","doi":"10.1016/j.annder.2025.103464","DOIUrl":"10.1016/j.annder.2025.103464","url":null,"abstract":"<div><h3>Background</h3><div>Alleviating sleep disturbances is a key therapeutic goal in pruritic dermatoses. However, sleep disturbance remains under-investigated in patients with bullous pemphigoid (BP), despite contributing to exhaustion in older adults and potentially increasing disease morbidity.</div></div><div><h3>Objectives</h3><div>To estimate the prevalence and severity of insomnia in BP patients, and examine its correlation with disease activity, self-rated pruritus, and quality of life (QoL).</div></div><div><h3>Method</h3><div>A national, multicenter, controlled study in 61 BP patients and 61 age- and sex-matched controls. Insomnia severity was assessed via the Insomnia Severity Index (ISI), BP activity via the Bullous Pemphigoid Disease Area Index (BPDAI), and QoL via the Autoimmune Bullous Disease Quality of Life (ABQOL) and ItchyQoL scores. Pruritus severity was rated using a numerical scale (NRS-pruritus). All assessments were repeated after one month of treatment.</div></div><div><h3>Results</h3><div>Significant sleep disorders (ISI ≥ 15) were observed in 34.4 % of cases and 8.5 % of controls (RR: 4.04; 95 % CI: 1.64–10.06; p = 0.0025). Significant sleep disorder was associated with higher ItchyQoL, ABQOL, and NRS-pruritus scores. However, the ItchyQoL score was the only independent factor (OR = 1.13; 95 % CI: 1.02–1.25). After one month of treatment, significant insomnia decreased by 56.2 % compared to baseline (p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>BP is associated with a four-fold risk of insomnia compared to age- and sex-matched controls. Screening for insomnia and promoting sleep quality should be part of BP treatment strategies.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103464"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tofacitinib-induced paradoxical psoriasis in a patient with ankylosing spondylitis: A case report","authors":"G.I. Kurmuş ,&nbsp;H. Kaya Akış ,&nbsp;H. Karataş ,&nbsp;A. Gökçe ,&nbsp;S.P. Kartal","doi":"10.1016/j.annder.2025.103462","DOIUrl":"10.1016/j.annder.2025.103462","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103462"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive mycosis fungoides with ocular involvement and transformation to cerebral T-cell lymphoma: A case report and literature review","authors":"R.-A. Henry ,&nbsp;V. Pipelart ,&nbsp;H. Maillard","doi":"10.1016/j.annder.2025.103465","DOIUrl":"10.1016/j.annder.2025.103465","url":null,"abstract":"","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103465"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145964668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"REACT-PXE: a consensus on diagnosis and future research concerning pseudoxanthoma elasticum (PXE)","authors":"L. Martin ,&nbsp;W. Spiering ,&nbsp;K. Aelbrecht ,&nbsp;T. Aranyi ,&nbsp;C. Duranton ,&nbsp;N. Kiss ,&nbsp;E. Letavernier ,&nbsp;M. Medvecz ,&nbsp;M. Pfau ,&nbsp;P.I. Nevalainen ,&nbsp;L. Nollet ,&nbsp;V. Murro ,&nbsp;F. Szeri ,&nbsp;S. Väärämäki ,&nbsp;G. Leftheriotis ,&nbsp;O.M. Vanakker","doi":"10.1016/j.annder.2025.103440","DOIUrl":"10.1016/j.annder.2025.103440","url":null,"abstract":"<div><div>Pseudoxanthoma elasticum (PXE) is an autosomal recessive disorder described more than 150 years ago in which calcification and fragmentation of the elastic fibers result in a variety of symptoms which differ greatly in presentation and severity between patients. The diagnosis of PXE can still be made in many patients based on clinical presentation. However, in the advent of genetic screening that followed upon the identification of the first causal gene, <em>ABCC6,</em> milder cases of PXE or patients with a less typical onset of disease surfaced. Moreover, it became clear in the last years that PXE has at least one allelic disorder which can also result from (identical) <em>ABCC6</em> or <em>ENPP1</em> pathogenic variants, namely generalized arterial calcification of infancy (GACI). These recent evolutions lead to challenges in making the correct diagnosis in a given number of patients. As emerging possibilities to treat PXE require a definite diagnosis, a critical re-appraisal of the diagnostic criteria for PXE − taking into account new clinical, biochemical and molecular characteristics – appeared to be necessary.</div><div>The REACT-PXE (Research, Education and Advanced Care Teams for PXE) Consortium − gathering most European experts on PXE − has been established to take on this task as a first step in updating the management of PXE. This paper presents an updated, evidence-based definition of PXE, revised diagnostic criteria, “red flags” for considering PXE, and a patient-centered approach to identifying meaningful outcomes. All skin, ocular, vascular and other disease manifestations are addressed and illustrated, followed by specific chapters on molecular genetics and biological alterations. All these efforts are designed to improve disease management, consider future treatment for all patients, with or without molecular definition of their condition, enhance patient care, and inform for future research directions.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103440"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145920968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The first year of treatment with selumetinib for NF1-related plexiform neurofibroma is medically challenging in real-life settings","authors":"P. Boitez ,&nbsp;D. Farges ,&nbsp;M. Descamps ,&nbsp;V. Bournazel ,&nbsp;L. Martin","doi":"10.1016/j.annder.2025.103438","DOIUrl":"10.1016/j.annder.2025.103438","url":null,"abstract":"<div><h3>Background</h3><div>Plexiform neurofibromas (PNFs) occur in 20–50 % of NF1 patients and can alter skin appearance and/or invade adjacent structures. These tumors grow rapidly in childhood, leading to significant morbidity. Surgical treatment is recommended as first-line therapy, but complete resection is not always possible, and the risk of recurrence is high. Selumetinib is a selective inhibitor of MEK protein kinases that has been shown to reduce PNF tumor volume. It has been approved as monotherapy for the treatment of symptomatic inoperable PNF in children aged over 3 years. The aim of our study was to investigate the real-life efficacy and safety profile of selumetinib in a single-center cohort of NF1 patients with one or more symptomatic inoperable PNFs.</div></div><div><h3>Patients and methods</h3><div>Prior to treatment, patients underwent cardiac ultrasound, ophthalmological examination, biological tests, and baseline magnetic resonance imaging (MRI). Specific patient follow-up included a quarterly consultation (with comparative pictures) and a monthly teleconsultation for the first 4 months to discuss any adverse effects, give advice, and provide support to patients and their families. Monitoring included biological, ophthalmological, cardiological and radiological assessment.</div></div><div><h3>Results</h3><div>From a pediatric NF1 cohort of over one hundred children, we included 10 patients over the age of 18 months (median age 14 years − range 5 to 17 years). Morbidities engendered by PNFs were disfigurement (50 %), pain (30 %), visual impairment (20 %) (mainly amblyopia), hearing impairment (10 %), and balance disorders (10 %). Selumetinib was administered at a dose of 25 mg/m²/day. After a median follow-up period of 19.5 months (±6.6 months), tumor volume shrinkage was observed clinically in 6 cases, stability in 2 cases, and volume growth in 2 cases.</div><div>Adverse events were mainly cutaneous (70 %), with acneiform rashes (60 %), xerosis cutis (20 %), alopecia (20 %), paronychia (10 %) and eczematous rash (10 %). Four patients (40 %) presented gastrointestinal disorders at the start of treatment. All these effects corresponded to grade 1 toxicity. No ocular or cardiac toxicity was detected.</div></div><div><h3>Discussion</h3><div>Our efficacy results at 19.5 months for selumetinib show a genuine but modest reduction in PNF volume. The treatment has a good safety profile. While it is very common for adverse events to be reported at the start of treatment, they are of moderate severity and are managed by dose reduction or simple symptomatic treatment. Starting treatment early in life appears to lead to a more favorable outcome and should be considered.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"153 1","pages":"Article 103438"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145780158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}